Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.11)
# 3,407
Out of 4,814 analysts
107
Total ratings
24.21%
Success rate
-11.89%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Maintains: Buy | $12 → $21 | $9.98 | +110.42% | 5 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $7.16 | +249.16% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $3.16 | +280.35% | 5 | Mar 13, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $23 → $15 | $3.14 | +378.47% | 3 | Feb 28, 2025 | |
| BIIB Biogen | Maintains: Buy | $298 → $265 | $118.61 | +123.42% | 20 | Feb 13, 2025 | |
| SAGE Sage Therapeutics | Maintains: Hold | $9 → $8 | $7.43 | +7.67% | 5 | Feb 12, 2025 | |
| CYBN Cybin | Maintains: Buy | $86 → $73 | $7.30 | +900.00% | 7 | Feb 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $172 → $163 | $100.10 | +62.84% | 14 | Feb 7, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $112 → $80 | $1.70 | +4,605.88% | 7 | Jan 6, 2025 | |
| GHRS GH Research | Maintains: Buy | $31 → $28 | $9.10 | +207.69% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $1.48 | +643.24% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $83 | $3.00 | +2,666.67% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $5.77 | +142.63% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $7.71 | +159.40% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $26 | $1.21 | +2,057.68% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $14.71 | +124.34% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $20.35 | +637.10% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $13.64 | - | 2 | Jan 31, 2017 |
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $12 → $21
Current: $9.98
Upside: +110.42%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $7.16
Upside: +249.16%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.16
Upside: +280.35%
COMPASS Pathways
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $15
Current: $3.14
Upside: +378.47%
Biogen
Feb 13, 2025
Maintains: Buy
Price Target: $298 → $265
Current: $118.61
Upside: +123.42%
Sage Therapeutics
Feb 12, 2025
Maintains: Hold
Price Target: $9 → $8
Current: $7.43
Upside: +7.67%
Cybin
Feb 12, 2025
Maintains: Buy
Price Target: $86 → $73
Current: $7.30
Upside: +900.00%
Neurocrine Biosciences
Feb 7, 2025
Maintains: Buy
Price Target: $172 → $163
Current: $100.10
Upside: +62.84%
BioXcel Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.70
Upside: +4,605.88%
GH Research
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $9.10
Upside: +207.69%
Nov 18, 2024
Maintains: Buy
Price Target: $11
Current: $1.48
Upside: +643.24%
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $3.00
Upside: +2,666.67%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $5.77
Upside: +142.63%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $7.71
Upside: +159.40%
Apr 30, 2024
Maintains: Buy
Price Target: $36 → $26
Current: $1.21
Upside: +2,057.68%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $14.71
Upside: +124.34%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $20.35
Upside: +637.10%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $13.64
Upside: -